Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19
November 05, 2020 16:01 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc.("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10
November 05, 2020 16:01 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19
October 26, 2020 16:01 ET
|
Aerpio Pharmaceuticals, Inc.
The trial in moderate-to-severe patients is Aerpio’s second clinical trial in COVID-19 patients and is funded in part by the U.S. military The military-sponsored trial is complementary to the...
Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial
September 15, 2020 08:30 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc.("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients
September 01, 2020 16:30 ET
|
Aerpio Pharmaceuticals, Inc.; Quantum Leap Healthcare Collaborative™
SAN FRANCISCO and CINCINNATI, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today...
Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update
August 12, 2020 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
Initiated a Phase 2 Open Angle Glaucoma Trial; Recruiting Ahead of ScheduleAnnounced Partnership with I-SPY to Participate in a Clinical Trial to Treat ARDS in COVID-19 PatientsAnnounced a Second...
Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12
August 10, 2020 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19
August 04, 2020 16:15 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through the Medical Technology Enterprise Consortium (MTEC)...
Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial
June 24, 2020 08:00 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, June 24, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19
June 08, 2020 16:43 ET
|
Aerpio Pharmaceuticals, Inc.
CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the public health and safety concerns related to the novel...